Let me put some caveats on my question. I understand that:
* PeptiDream has more deals - 9 versus 6 * Petidream has cash in the bank - when clearly PYC doesn't * PeptiDream was cash flow positive last year - although that might have been more a function of deals done in that particular year than ongoing? * PeptiDream is based in Japan - whereas PYC is in Perth - not exactly a hub of financial/scientific activity on a worldwide scale.
Still, even discounting all this, and then some, the gap is still HUGE.
If the science is comparable, then perhaps PYC has more too it than is currently being priced in - and perhaps this is where Griffin will come into it - connecting players, deals, sourcing capital, etc...
Interesting times and I'm looking forward to seeing the presentations from the next few days. In the meantime, is anyone able to draw a comparison on the science between the two?
Thanks
PYC Price at posting:
1.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)